EANM Young Scientist Network (YSN) Award

To be eligible, applicants must meet the following requirements: 

• Be an early-career physician scientist with a demonstrated interest in α-RLT, including PhD candidates, postdoctoral fellows, junior faculty members, or clinicians in training 
• Have no more than 10 years of experience beyond their terminal degree (including clinical training periods) 
• Be affiliated with a recognised academic, clinical, or research institution in a country represented by an EANM National Member Society 

 Each application must include: 

1. A concise curriculum vitae highlighting academic qualifications, clinical training, research experience, and publications 
2. A career statement (maximum 1 page) describing motivation, long term goals in α-RLT, and how the award will support professional development toward independence 
3. A project abstract (maximum 1 page) summarising objectives, methods, and expected impact 
4. A letter of support signed by the department chair
5. A project proposal (maximum 5 pages) outlining: 

• Scientific background and specific aims 
• Methodological approach 
• Timeline (12 to 24 months) 
• Justified budget 
• Expected outcomes, including at least one peer reviewed publication and a presentation at an international congress, with priority given to the EANM journals and the EANM Annual Congress 

Targeted radionuclide therapy, particularly α-RLT, is an emerging pillar of precision oncology with strong early clinical efficacy but unresolved challenges in toxicity management, patient selection, and clinical integration. Addressing these gaps requires coordinated basic, translational, and early-phase clinical research. The Young Scientist Network will mobilise early-career physician-scientists to accelerate innovative α-RLT research – initially in prostate cancer – bridging promising concepts to clinical impact.  

Projects should aim to deliver clinically meaningful advances in α-RLT. Priority areas include: 

• Optimising clinical use: Projects addressing treatment planning, response monitoring, toxicity management, and integration of α-RLT into routine patient care. 
• Personalising therapy and improving outcomes: Approaches that tailor α-RLT to individual patients using biomarkers, imaging, or other decision support tools to maximise efficacy and safety. 
• Clinical translation and patient selection: Studies focusing on identifying patients most likely to benefit from α-RLT, including early phase clinical trial design, innovative patient stratification strategies, and the integration of emerging tools such as artificial intelligence. 

For the 2026 edition, the scientific focus will be on prostate cancer, with future editions expanding to additional malignancies. 

Applications will be evaluated by an independent scientific reviewing committee appointed by EANM and composed of experts in nuclear medicine, oncology, medical physics, radiochemistry, and translational research. 

 Projects will be assessed by the scientific reviewing committee based on:  

• Scientific merit (novelty, rigour, feasibility) 
• Relevance to advancing α-RLT 
• Clinical impact and translational potential 
• Contribution of the project to the candidate’s professional growth and independence 

 A transparent 1–9 scoring system, aligned with European funding frameworks, will be applied. 

All scientific and administrative aspects of the award are fully governed by EANM to ensure independence, fairness, and transparency. 

Funding 

A total budget of 100,000 EUR will be allocated by an independent scientific reviewing committee using a tiered funding model: 

• Platinum Award: 40,000 EUR 
• Gold Award: 20,000 EUR 
• Silver Award: 10,000 EUR 

There is no predefined number of awardees. Funding levels and the number of awarded projects will depend on scientific merit, project scope, and funding needs, and will be determined by the independent scientific reviewing committee. 

 The awarded funding, which will be administered through the awardee’s host department, may be used to: 

• Undertake research stays in centres with established α-RLT expertise 
• Receive mentorship and guidance to strengthen clinical and methodological skills 
• Integrate novel approaches into ongoing clinical or translational work, enhancing independence and leadership potential 
• Establish collaborative projects across disciplines (physics, radiochemistry, oncology) 

The award complements the candidate’s current clinical and research activities by providing access to advanced facilities and expertise that accelerate career development towards independent scientist roles. 

Networking & visibility 

In addition to receiving funding, awardees will have the opportunity to exchange ideas and further develop their project at two dedicated events at the EANM’26 Annual Congress in Vienna (Austria) on October 17-21, 2026:

1. YSN Award kick off session 

• Project presentations by awardees 
• Open audience 

2. Follow up workshop for awardees 

• Interactive workshop to further develop awarded projects 
• Restricted to awardees and the scientific reviewing committee 

Awardees will also be expected to present their results at a subsequent EANM Annual Congress. 

Awardees are expected to submit: 

• An interim report at 6 months 
• A final report at project completion (12 months) 

These reports ensure accountability, monitor progress, and support dissemination of results within the nuclear medicine community. 

• Submissions open: Monday, February 16, 2026 
• Submissions close: Monday, May 18, 2026 (23:59 CEST) 
• Notification of selected candidates: After July 23, 2026 
• EANM’26 Annual Congress: October 17-21, 2026 

Please send all required documents listed in the “Eligibility & Application Requirements” section by Monday, May 18, 2026 (23:59 CEST) via e-mail to ysn@eanm.org.  

Don’t hesitate to reach out to us if you have any questions!